BioLineRx (BLRX) Current Leases (2019 - 2026)
BioLineRx (BLRX) posted quarterly Current Leases of $977000.0 for Q4 2025, down 9.62% year-over-year from $1.1 million in Q4 2024, and down 2.59% quarter-over-quarter from $1.0 million in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Current Leases (2019 - 2026) Analysis & Trends
BioLineRx's Current Leases history runs 7 years deep, the most recent figure standing at $977000.0 for Q4 2025.
- In Q4 2025, Current Leases fell 9.62% year-over-year to $977000.0; the TTM figure through Dec 2025 stood at $977000.0 (down 9.62% YoY), while the FY2025 annual figure was $977000.0, down 9.62% from the prior year.
- Current Leases for Q4 2025 stood at $977000.0, down from $1.0 million in the prior quarter.
- The five-year high for Current Leases was $1.7 million in Q4 2022, with the low at $977000.0 in Q4 2025.
- The 5-year median for Current Leases is $1.4 million (2022), against an average of $1.4 million.
- The sharpest annual moves came in 2023 and 2024: Current Leases climbed 9.44% in 2023, then retreated 27.79% in 2024.
- BioLineRx's Current Leases stood at $1.7 million in 2021, then climbed by 0.17% to $1.7 million in 2022, then dropped by 25.39% to $1.3 million in 2023, then retreated by 16.2% to $1.1 million in 2024, then decreased by 9.62% to $977000.0 in 2025.
- Business Quant data shows BLRX's Current Leases at $977000.0 in Q4 2025, $1.0 million in Q3 2025, and $998000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | BioLineRx | 6.64 Bn | 6.64 Bn | 235,000.00 | 280,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 280,000.00 |
| Mar 31, 2026 | 253,000.00 |
| Dec 31, 2025 | 234,000.00 |
| Sep 30, 2025 | 297,000.00 |
| Jun 30, 2025 | 408,000.00 |
| Mar 31, 2025 | 440,000.00 |
| Dec 31, 2024 | 522,000.00 |
| Sep 30, 2024 | 517,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 467,000.00 |
| Dec 31, 2023 | 528,000.00 |
| Sep 30, 2023 | 526,000.00 |
| Jun 30, 2023 | 375,000.00 |
| Mar 31, 2023 | 379,000.00 |
| Dec 31, 2022 | 427,000.00 |
| Sep 30, 2022 | 151,000.00 |
| Jun 30, 2022 | 149,000.00 |
| Mar 31, 2022 | 1.66 Mn |
| Dec 31, 2021 | 168,000.00 |
| Sep 30, 2021 | 1.68 Mn |